Peptides for Heart Regeneration After a Heart Attack
Peptides and Cardiac Repair
60% reduction
Mitochondria-targeted peptide SS-31 reduced myocardial infarct size by up to 60% in rat models of ischemia-reperfusion injury.
Cho et al., Journal of Biological Chemistry, 2007
Cho et al., Journal of Biological Chemistry, 2007
View as imageA heart attack kills approximately one billion cardiomyocytes within hours. Adult human heart muscle has almost no regenerative capacity, so those cells are replaced by scar tissue that cannot contract. The result is permanent loss of pumping function and, in many cases, progressive heart failure. Peptide-based approaches to cardiac repair aim to change this equation by protecting surviving cardiomyocytes, stimulating new blood vessel growth, mobilizing cardiac progenitor cells, or reducing the inflammatory damage that follows reperfusion.[1] No peptide has yet restored lost heart muscle in humans, but several have produced striking results in animal models and early clinical trials. This article reviews what the evidence shows for each approach, including connections to the broader cardiac peptide research landscape.
Key Takeaways
- The mitochondria-targeted peptide SS-31 (elamipretide) reduced myocardial infarct size by up to 60% in rat ischemia-reperfusion models by preserving mitochondrial electron transport (Cho et al., Journal of Biological Chemistry, 2007)
- SS-31 also ameliorated hypertensive cardiomyopathy in rats, reducing cardiac fibrosis, hypertrophy, and diastolic dysfunction through mitochondrial antioxidant protection (Dai et al., Annals of Internal Medicine, 2011)
- Three GHRH agonists (JI-38, MR-356, MR-409) reduced infarct size in rats and increased cardiac c-kit+ progenitor cells, the heart's own stem cells, suggesting regenerative rather than purely protective effects (Kanashiro-Takeuchi et al., PNAS, 2015)
- BPC-157 prevented methyldigoxin-induced arrhythmias in rats through nitric oxide signaling, adding antiarrhythmic potential to its tissue-protective profile (Balenovic et al., 2009)
- Thymosin beta-4 protects endothelial cells from damage through microRNA-34a inhibition, supporting its role in vascular repair after cardiac injury (Chen et al., 2019)
- Semaglutide reduced major adverse cardiovascular events across a continuum of cardiovascular risk, demonstrating that GLP-1 receptor agonists have cardioprotective effects beyond metabolic improvement (Husain et al., Circulation, 2020)
Why the Heart Cannot Repair Itself
Unlike liver, skin, or bone, adult mammalian heart muscle regenerates at a rate of less than 1% per year. A typical myocardial infarction destroys 10-25% of the left ventricular mass in a matter of hours. The body responds with inflammation (which clears dead cells but also damages surviving tissue), fibrosis (scar formation that prevents cavity rupture but cannot contract), and compensatory hypertrophy of remaining cardiomyocytes (which increases wall stress and can lead to further failure).
Every peptide approach to cardiac repair targets one or more of these three problems: cell death during the acute event, destructive inflammation in the days that follow, or the inability to replace lost contractile tissue.
Mitochondria-Targeted Peptides: SS-31 (Elamipretide)
The most clinically advanced peptide approach to cardiac protection targets mitochondria directly. SS-31 (also known as elamipretide or Bendavia) is a four-amino-acid peptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that concentrates in the inner mitochondrial membrane, where it stabilizes cardiolipin and preserves electron transport chain function during ischemia and reperfusion.
Cho and colleagues demonstrated in 2007 that SS-31 reduced myocardial infarct size by up to 60% in a rat ischemia-reperfusion model. The peptide was effective both when administered before ischemia and when given at the time of reperfusion, a finding with direct clinical relevance since most heart attack patients present after the ischemic event has begun.[1]
Dai and colleagues extended these findings in 2011, showing that chronic SS-31 treatment ameliorated hypertensive cardiomyopathy in rats. The peptide reduced cardiac fibrosis, ventricular hypertrophy, and diastolic dysfunction by protecting mitochondria from oxidative damage caused by sustained high blood pressure.[2]
SS-31 reached Phase 2 clinical trials for acute myocardial infarction (the EMBRACE-STEMI trial). Results were mixed: a single intravenous dose of elamipretide (0.25 mg/kg) during percutaneous coronary intervention did not reduce overall infarct size, but it was associated with reduced incidence of heart failure within 24 hours following the procedure. The FDA approved elamipretide in 2025 for Barth syndrome, a rare mitochondrial cardiomyopathy, validating the mechanism in human cardiac tissue even if the acute MI application requires further development.
GHRH Agonists: Stimulating Cardiac Stem Cells
A different regenerative strategy uses growth hormone-releasing hormone (GHRH) agonists to activate the heart's own progenitor cell population. Kanashiro-Takeuchi and colleagues published a landmark 2015 study demonstrating that three synthetic GHRH agonists (JI-38, MR-356, and MR-409) reduced myocardial infarct size in rats after four weeks of treatment.[3]
The mechanism was not simple protection. Treated hearts showed increased numbers of cardiac c-kit+ progenitor cells (the heart's resident stem cells), more proliferating cardiomyocytes, and enhanced new blood vessel formation (angiogenesis) within the infarct zone. This suggests GHRH agonists may stimulate actual regeneration, not just prevent further damage.
GHRH receptors are expressed on cardiomyocytes and cardiac fibroblasts, providing a direct mechanism for these effects independent of systemic growth hormone release. The distinction matters: systemic GH elevation carries concerns about insulin resistance, fluid retention, and potential tumor promotion. Direct cardiac GHRH receptor activation may provide the regenerative stimulus without these systemic effects, though this has not been tested in human cardiac patients.
BPC-157: Antiarrhythmic and Tissue-Protective
BPC-157 (Body Protection Compound-157), a pentadecapeptide derived from human gastric juice, has accumulated a broad animal literature across multiple organ systems. Its cardiac applications center on antiarrhythmic and tissue-protective effects.
Balenovic and colleagues demonstrated in 2009 that BPC-157 prevented methyldigoxin-induced cardiac arrhythmias in rats. The mechanism involved the nitric oxide signaling system: L-NAME (an NO synthase inhibitor) attenuated BPC-157's protective effect, while L-arginine (an NO precursor) enhanced it.[4]
This NO-mediated cardioprotection aligns with BPC-157's effects in other vascular beds, where it promotes angiogenesis, protects endothelial function, and modulates inflammatory pathways. In the context of myocardial infarction, these properties could address both the acute ischemic injury and the subsequent inflammatory damage.
The limitation: all BPC-157 cardiac research is preclinical. No human cardiac trials have been conducted, and the peptide is not an approved pharmaceutical in any jurisdiction. The gap between animal models of drug-induced arrhythmia and human myocardial infarction is substantial.
Thymosin Beta-4: Vascular Repair
Thymosin beta-4 (TB4) has received attention for cardiac applications based on its ability to promote cell migration, angiogenesis, and tissue remodeling. Chen and colleagues demonstrated in 2019 that TB4 protects endothelial cells from damage through inhibition of microRNA-34a, a pathway that preserves vascular integrity after cardiac injury.[5]
In animal models of myocardial infarction, TB4 treatment has been shown to reduce infarct size, improve cardiac function, and promote new blood vessel formation in the peri-infarct zone. The peptide appears to activate epicardial progenitor cells, a population of cells in the heart's outer layer that can differentiate into smooth muscle cells and potentially cardiomyocytes. For more on this peptide's broader biology, see thymosin beta-4 and cardiac repair and TB-500, the synthetic fragment.
The copper peptide GHK-Cu represents another wound-healing peptide with emerging cardiac applications, though its evidence base is smaller than TB4's.
Natriuretic Peptides and GLP-1 Agonists: Established Cardiac Peptides
Two peptide classes already have established roles in cardiovascular medicine, though not for regeneration per se.
Natriuretic peptides (ANP, BNP, CNP) are endogenous cardiac hormones that reduce blood volume, decrease blood pressure, and protect against pathological cardiac remodeling. Rubattu and colleagues reviewed the therapeutic landscape in 2008, including the development of nesiritide (recombinant BNP for acute heart failure) and the concept of neprilysin inhibition to boost endogenous natriuretic peptide levels.[6] The latter concept became sacubitril/valsartan (Entresto), now a standard heart failure therapy. For more on this system, see how natriuretic peptides protect your heart and kidneys and the history of nesiritide.
A 2025 Columbia University study took natriuretic peptides in a regenerative direction, using self-amplifying RNA to upregulate pro-ANP (pro-atrial natriuretic peptide) in mice after myocardial infarction. Treated mice showed a two-fold increase in serum pro-ANP levels and doubled left ventricular function at four weeks compared to untreated controls, with reduced fibrosis. This is not yet a peptide drug per se but demonstrates that boosting endogenous natriuretic peptide production has regenerative potential.
GLP-1 receptor agonists like semaglutide have demonstrated cardiovascular protection in large clinical trials. Husain and colleagues reported in 2020 that semaglutide reduced major adverse cardiovascular events (cardiovascular death, non-fatal stroke, non-fatal MI) across a continuum of cardiovascular risk levels.[7] The mechanism likely involves anti-inflammatory effects, improved endothelial function, and reduced atherosclerotic plaque burden rather than direct myocardial regeneration.
Delivery Matters: How Peptides Reach Damaged Heart Tissue
A peptide that works in a test tube or even in systemic circulation may never reach the infarct zone in therapeutic concentrations. Several delivery innovations are being developed specifically for cardiac peptide applications.
Peptide nanofiber scaffolds. Synthetic glycosaminoglycan-mimetic peptide nanofibers, injected directly into infarct sites, form a temporary extracellular matrix that supports cell infiltration and new blood vessel growth. A 2017 study demonstrated that these scaffolds recruited vascular cells, induced neovascularization, and improved cardiac performance in rat MI models. The scaffold provides both physical support for the damaged tissue and a sustained local concentration of bioactive peptide signals.
Injectable hydrogels. Bioactive peptide-loaded hydrogels combine antioxidant and pro-angiogenic peptides in a single injectable matrix. Published in 2025, these composite hydrogels scavenge reactive oxygen species (which cause reperfusion injury) while simultaneously promoting new blood vessel formation. The dual function addresses two critical post-infarction problems with one intervention.
RNA-delivered peptide gene therapy. Rather than injecting the peptide itself, this approach delivers genetic instructions (self-amplifying RNA) that cause the heart's own cells to produce the therapeutic peptide locally. The 2025 Columbia University pro-ANP study used this strategy to achieve sustained natriuretic peptide elevation directly in cardiac tissue, producing the doubling of left ventricular function described above.
Each delivery method addresses a different limitation: scaffolds provide structural support, hydrogels offer sustained local release, and gene therapy enables endogenous production. Whether any of these will succeed in human cardiac applications is unknown.
The Translation Gap
The distance between animal cardiac studies and human clinical applications deserves direct acknowledgment. Rodent hearts regenerate more readily than human hearts. Surgical ischemia-reperfusion models differ from the gradual atherosclerotic occlusions that cause most human heart attacks. The timing of peptide administration in animal studies (often minutes before or after the insult) does not match real-world clinical scenarios where hours pass between symptom onset and treatment.
The EMBRACE-STEMI trial illustrated this gap. SS-31 reduced infarct size by 60% in rats but showed no significant infarct size reduction in humans when given as a single dose during PCI. The 24-hour heart failure reduction signal was encouraging but needs confirmation in larger trials.
Of 41 cardiac regeneration clinical trials identified in a recent pipeline analysis, 23 met inclusion criteria. Most were early-phase (11 Phase 1, 9 Phase 2, 3 Phase 3), with myocardial infarction as the most common target (9 trials), followed by heart failure (8) and coronary artery disease (5). The field is active but early-stage, with no peptide-based regenerative therapy yet reaching Phase 3 for acute MI.
The Bottom Line
Four distinct peptide strategies target cardiac repair after heart attack: mitochondria-targeted antioxidant peptides (SS-31/elamipretide), growth factor agonists that activate cardiac progenitor cells (GHRH agonists), tissue-protective peptides that modulate inflammation and angiogenesis (BPC-157, thymosin beta-4), and endogenous cardiac hormones that reduce pathological remodeling (natriuretic peptides). SS-31 has the most advanced clinical data, with Phase 2 results showing a heart failure reduction signal despite missing its primary infarct size endpoint. All approaches face a significant translation gap between animal model efficacy and human clinical benefit. No peptide has yet demonstrated human cardiomyocyte regeneration.